- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: May 2019
- Public Summary Document (PSD) May 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) May 2019 PBAC Meeting - Word
Blinatumomab – May 2019
Blinatumomab: Powder for I.V. infusion, 38.5 micrograms; Blincyto®
Last updated
1 November 2019